Cargando…
The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial
OBJECTIVES: In general populations, the adverse effects of smoking on coronary risk have been demonstrated to be greater in women than in men; whether this is true for individuals with diabetes is unclear. DESIGN: Cohort study. SETTING: 20 countries worldwide participating in the ADVANCE (Action in...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716176/ https://www.ncbi.nlm.nih.gov/pubmed/26747037 http://dx.doi.org/10.1136/bmjopen-2015-009668 |
_version_ | 1782410516043399168 |
---|---|
author | Blomster, Juuso I Woodward, Mark Zoungas, Sophia Hillis, Graham S Harrap, Stephen Neal, Bruce Poulter, Neil Mancia, Giuseppe Chalmers, John Huxley, Rachel |
author_facet | Blomster, Juuso I Woodward, Mark Zoungas, Sophia Hillis, Graham S Harrap, Stephen Neal, Bruce Poulter, Neil Mancia, Giuseppe Chalmers, John Huxley, Rachel |
author_sort | Blomster, Juuso I |
collection | PubMed |
description | OBJECTIVES: In general populations, the adverse effects of smoking on coronary risk have been demonstrated to be greater in women than in men; whether this is true for individuals with diabetes is unclear. DESIGN: Cohort study. SETTING: 20 countries worldwide participating in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. PARTICIPANTS: 11 140 patients with type 2 diabetes aged ≥55 years and in cardiovascular risk at the time of randomisation. PRIMARY AND SECONDARY OUTCOME MEASURES: Major cardiovascular events (death from cardiovascular disease, non-fatal stroke or non-fatal myocardial infarction (MI)), all cardiovascular events (major cardiovascular event or peripheral arterial disease or transient ischaemic attack), and all-cause mortality. Secondary outcome measures were major coronary events (fatal and non-fatal MI), major cerebrovascular events (fatal and non-fatal stroke), nephropathy (new or worsening renal disease), and all cancer. RESULTS: At baseline, 6466 (56% women) participants were never-smokers, 1550 (28% women) were daily smokers and 3124 (21% women) were former smokers. Median follow-up time was 5 years. In Cox regression models after multiple adjustments, compared with never smoking, daily smoking was associated with increased risk of all primary and secondary outcomes with the exception of major cerebrovascular disease. Only for major coronary events was there any evidence of a stronger effect in women than in men (ratio of the adjusted HRs women:men; 1.64 (0.83 to 3.26) p=0.08). For all other outcomes considered, the hazards of smoking were similar in men and women. Quitting smoking was associated with a 30% reduction in all-cause mortality (p=0.001) in both sexes. CONCLUSIONS: In individuals with diabetes, the effects of smoking on all major forms of cardiovascular disease are equally as hazardous in women and men with the possible exception of major coronary events where there was some evidence of a greater hazard in women. TRIAL REGISTRATION NUMBER: NCT00145925. |
format | Online Article Text |
id | pubmed-4716176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-47161762016-01-31 The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial Blomster, Juuso I Woodward, Mark Zoungas, Sophia Hillis, Graham S Harrap, Stephen Neal, Bruce Poulter, Neil Mancia, Giuseppe Chalmers, John Huxley, Rachel BMJ Open Smoking and Tobacco OBJECTIVES: In general populations, the adverse effects of smoking on coronary risk have been demonstrated to be greater in women than in men; whether this is true for individuals with diabetes is unclear. DESIGN: Cohort study. SETTING: 20 countries worldwide participating in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. PARTICIPANTS: 11 140 patients with type 2 diabetes aged ≥55 years and in cardiovascular risk at the time of randomisation. PRIMARY AND SECONDARY OUTCOME MEASURES: Major cardiovascular events (death from cardiovascular disease, non-fatal stroke or non-fatal myocardial infarction (MI)), all cardiovascular events (major cardiovascular event or peripheral arterial disease or transient ischaemic attack), and all-cause mortality. Secondary outcome measures were major coronary events (fatal and non-fatal MI), major cerebrovascular events (fatal and non-fatal stroke), nephropathy (new or worsening renal disease), and all cancer. RESULTS: At baseline, 6466 (56% women) participants were never-smokers, 1550 (28% women) were daily smokers and 3124 (21% women) were former smokers. Median follow-up time was 5 years. In Cox regression models after multiple adjustments, compared with never smoking, daily smoking was associated with increased risk of all primary and secondary outcomes with the exception of major cerebrovascular disease. Only for major coronary events was there any evidence of a stronger effect in women than in men (ratio of the adjusted HRs women:men; 1.64 (0.83 to 3.26) p=0.08). For all other outcomes considered, the hazards of smoking were similar in men and women. Quitting smoking was associated with a 30% reduction in all-cause mortality (p=0.001) in both sexes. CONCLUSIONS: In individuals with diabetes, the effects of smoking on all major forms of cardiovascular disease are equally as hazardous in women and men with the possible exception of major coronary events where there was some evidence of a greater hazard in women. TRIAL REGISTRATION NUMBER: NCT00145925. BMJ Publishing Group 2016-01-08 /pmc/articles/PMC4716176/ /pubmed/26747037 http://dx.doi.org/10.1136/bmjopen-2015-009668 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Smoking and Tobacco Blomster, Juuso I Woodward, Mark Zoungas, Sophia Hillis, Graham S Harrap, Stephen Neal, Bruce Poulter, Neil Mancia, Giuseppe Chalmers, John Huxley, Rachel The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial |
title | The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial |
title_full | The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial |
title_fullStr | The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial |
title_full_unstemmed | The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial |
title_short | The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial |
title_sort | harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the advance (action in diabetes and vascular disease: preterax and diamicron modified release controlled evaluation) trial |
topic | Smoking and Tobacco |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716176/ https://www.ncbi.nlm.nih.gov/pubmed/26747037 http://dx.doi.org/10.1136/bmjopen-2015-009668 |
work_keys_str_mv | AT blomsterjuusoi theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT woodwardmark theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT zoungassophia theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT hillisgrahams theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT harrapstephen theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT nealbruce theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT poulterneil theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT manciagiuseppe theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT chalmersjohn theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT huxleyrachel theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT blomsterjuusoi harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT woodwardmark harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT zoungassophia harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT hillisgrahams harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT harrapstephen harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT nealbruce harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT poulterneil harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT manciagiuseppe harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT chalmersjohn harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial AT huxleyrachel harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial |